Comparison of 10‐day levofloxacin bismuth‐based quadruple therapy and levofloxacin‐based triple therapy for <i>Helicobacter pylori</i>

Abstract

Adding bismuth subcitrate to levofloxacin-based triple therapy was not more effective than not doing so, but no further side effects were noted. Both eradication therapies were equally safe and patients had the same tolerance to both regimens. Resistance rate to levofloxacin may be important when choosing second-line therapy.